Home 2023

Novartis

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly
Bioprocessing

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly

Alex Philippidis -
0
mRNA Platforms and Purification: Challenges and Solutions
Drug Discovery

mRNA Platforms and Purification: Challenges and Solutions

Kathy Vuksanaj -
0
Novartis Bolsters Neuro Pipeline, RNA Capabilities with Up-to-$1B DTx Pharma Acquisition
News

Novartis Bolsters Neuro Pipeline, RNA Capabilities with Up-to-$1B DTx Pharma Acquisition

Alex Philippidis -
0
StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy
Drug Discovery

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy

Alex Philippidis -
437
Novartis to Buy Chinook for Up to $3.5B, Expanding Kidney Disease Pipeline
Drug Discovery

Novartis to Buy Chinook for Up to $3.5B, Expanding Kidney Disease Pipeline

Alex Philippidis -
24
Life Sciences M&A: Drivers and Market Outlook
GEN Edge

Life Sciences M&A: Drivers and Market Outlook

Kathy Vuksanaj -
19
Novartis Takes a Systematic Approach to Exploring Immunogenicity
Bioprocessing

Novartis Takes a Systematic Approach to Exploring Immunogenicity

Christina Jackson -
0
HCP.Novartis.com
Best of the Web

HCP.Novartis.com

Christina Jackson -
0
Sangamo Eliminating 27% of U.S. Workforce, Refocusing Pipeline
Drug Discovery

Sangamo Eliminating 27% of U.S. Workforce, Refocusing Pipeline

Alex Philippidis -
0
Olema Plans Pivotal Trial for Two-Prong Breast Cancer Treatment
Cancer

Olema Plans Pivotal Trial for Two-Prong Breast Cancer Treatment

Alex Philippidis -
0
123...53Page 1 of 53
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.